Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Get news By email or subscribe to our News feeds.
Posted Today in Daily MedNews
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
U.S. Funding for Alzheimer's Research Increased
The U.S. National Institutes of Health will spend an extra $50 million on Alzheimer's research this year under a plan announced Tuesday, and the Obama administration plans to ask Congress for $80 million in new Alzheimer's research money for...
Read More... Posted Today in Daily MedNews.
TUESDAY, Feb. 7 -- Heart failure is linked to thinning of the bones and an increased risk of fractures, a new study indicates.
The findings suggest that aggressive screening for osteoporosis may be important for heart failure patients, the researchers said.
They looked at data from about 45,500 adults who underwent bone mineral density testing for the first time and were followed for up to 10...
Read More... Posted Today in Daily MedNews.
TUESDAY, Feb. 7 -- Routinely giving infants a new vaccine that guards against meningitis appears to be effective, a new study indicates.
The multi-center clinical trial of almost 1,900 infants found that administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis -- a bacterium that can cause serious disease such as sepsis and meningitis -- was effective...
Read More... Posted Today in Daily MedNews.
TUESDAY, Feb. 7 -- Despite earlier research that suggested the rotavirus vaccine increased the risk of intussusception -- when a portion of the intestine slides forward into itself -- a large new study finds this is not the case.
"The findings of our study are reassuring and add to the evidence that the benefits of rotavirus vaccine, in terms of reducing doctor's visits hospitalizations and...
Read More... Posted Today in Daily MedNews.
TUESDAY, Feb. 7 -- New antibiotics are needed to help treat bladder infections, but the drug cefpodoxime, once thought promising, doesn't appear to be up to the task, a new study indicates.
Bladder infections, more common in women than men, are usually treated with a short course of antibiotics. But overuse of mainstay medications, such as ciprofloxacin, has led to increasing rates of antibiotic...
Read More... Posted Today in New Drug Approvals.
BRIDGEWATER, N.J., Feb. 7, 2012 /PRNewswire/ -- Sanofi announced
today that the U.S. Food and Drug Administration (FDA) has approved
Sklice (ivermectin) lotion, 0.5% for the topical treatment of
head lice, in patients 6 months of age and older. Effective and
well-tolerated, Sklice Lotion treats lice in most patients with a
single 10-minute application of the lotion, without...
Read More... Posted Today in Pharma Industry News.
DEERFIELD, Ill., February 6,
2012 and Osaka, Japan, February 7, 2012 – Takeda
Pharmaceutical Company Limited (Takeda) and its wholly-owned
subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced
EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now
available by prescription in U.S. pharmacies for the treatment of
hypertension to lower blood pressure in adults. It is the...
Read More... Posted Today in Pharma Industry News.
From Canadian Press DataFile
(February 6, 2012)
By Sheryl Ubelacker
TORONTO _ A drug shown to be
highly effective in preventing breast cancer in postmenopausal
women at high risk for the disease appears to worsen age-related
bone loss, despite regular ingestion of calcium and vitamin D,
researchers have discovered.
In a study published last June,
the drug exemestane was found to be "very...
Read More... Posted 5 Days Ago in New Drug Approvals.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 2, 2012 - Merck, known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA)
approved Janumet XR (sitagliptin and
metformin hydrochloride (HCl) extended-release) tablets, a new
treatment for type 2 diabetes that combines sitagliptin, which is
the active component of Januvia
(sitagliptin),...
Read More... Posted 5 Days Ago in Pharma Industry News.
Are We Sure Our Drugs Are Safe? [St. Joseph News-Press (MO)]
From St. Joseph News-Press (MO) (February 1, 2012)
(CNN) -- When Americans pick up their prescriptions from the
pharmacy or reach for a prescription bottle from their medicine
cabinet, they probably don't think much about where the drugs were
made or whether they are safe.
What most Americans don't realize is the staggering fact...
Read More... Posted 6 Days Ago in New Drug Applications.
SAN DIEGO, and WOODCLIFF LAKE, N.J., Feb. 1, 2012 /PRNewswire/
-- Arena Pharmaceuticals, Inc. and Eisai Inc.
announced today that the US Food and Drug Administration (FDA) has
notified Arena that an Endocrinologic and Metabolic Drugs Advisory
Committee meeting to discuss the lorcaserin New Drug Application
(NDA) resubmission will be held in the second quarter of 2012.
Confirmation and...
Read More... Posted 6 Days Ago in Pharma Industry News.
Nearly half of surveyed oncologists saw tumors recur and
patients die sooner due to drug shortages; 73 percent substituted
sub-optimal care due to patient inability to afford drug
co-payments
PHILADELPHIA--(BUSINESS WIRE)--Feb 1, 2012 - A recently
completed
survey of U.S. oncologists reveals an oncology landscape that
is growing increasingly bleak due to a shortage of cancer drugs...
Read More... Posted 6 Days Ago in New Drug Approvals.
RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/
-- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and
Company today announced the U.S. Food and Drug
Administration (FDA) has approved Jentadueto
(linagliptin/metformin hydrochloride) tablets, a new tablet
combining the dipeptidyl peptidase-4 (DPP-4) inhibitor,
linagliptin, and metformin. Jentadueto provides a...
Read More... Posted 6 Days Ago in Pharma Industry News.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it
has voluntarily recalled 14 lots of Lo/Ovral-28 (norgestrel
and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl
Estradiol Tablets (generic)for customers in the U.S. market. An
investigation by Pfizer found that some blister packs may contain
an inexact count of inert or active ingredient tablets and that...
Read More... Posted 1 Weeks Ago in New Drug Approvals.
The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.
Gleevec was originally granted...
Read More... Posted 1 Weeks Ago in New Drug Approvals.
TUESDAY, January 31, 2012 -- The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.
CF is a serious genetic disorder affecting the lungs and other organs that ultimately leads to an early...
Read More... Posted 1 Weeks Ago in New Drug Applications.
BEDMINSTER, N.J.--(BUSINESS WIRE)--Jan 31, 2012 - NPS
Pharmaceuticals, Inc., a specialty pharmaceutical
company developing orphan therapeutics for rare gastrointestinal
and endocrine disorders, today announced the U.S. Food and Drug
Administration (FDA) has accepted and filed for review the
company's New Drug Application (NDA) for Gattex (teduglutide)
for the treatment of adults with short...
Read More... Posted 1 Weeks Ago in New Drug Applications.
NEW YORK--(BUSINESS WIRE)--Jan 27, 2012 - Pfizer Inc. announced
today that the U.S. Food and Drug Administration (FDA) has accepted
its New Drug Application (NDA) for standard review of bosutinib as
a treatment option for adult patients with previously treated
Philadelphia chromosome positive (Ph+) chronic myeloid leukemia
(CML). This submission was based on efficacy and safety data...
Read More... Posted 1 Weeks Ago in New Drug Applications.
SEATTLE, Jan. 30, 2012 /PRNewswire via COMTEX/ --Cell
Therapeutics, Inc. ("CTI") announced today
that it has voluntarily withdrawn its New Drug Application ("NDA")
for Pixuvri (pixantrone) for the treatment of relapsed or
refractory aggressive non-Hodgkin's lymphoma ("NHL") in patients
who failed two or more lines of prior therapy. The NDA was
withdrawn because, after communications with...
Read More... Posted 2 Weeks Ago in New Drug Applications.
MOUNTAIN VIEW, Calif., January 23, 2012, 2012 /PRNewswire/ --
Alexza Pharmaceuticals, Inc. announced today that the U.S. Food and
Drug Administration (FDA) will require additional time to complete
its review of the New Drug Application (NDA) for Adasuve
(Staccato loxapine).
In a notice received from the FDA, the Prescription Drug User
Fee Act (PDUFA) date for the Adasuve NDA has been...
Read More... Posted Today in Clinical Trials.
SEATTLE, Feb. 7, 2012 /PRNewswire/ -- Omeros Corporation
(NASDAQ: OMER) today announced that recent positive clinical
developments have allowed it to revise the planned analysis for its
ongoing Phase 3 clinical trial evaluating OMS302, which Omeros
believes expands opportunities for the product's clinical and
regulatory success. OMS302 is a proprietary combination of an
anti-inflammatory...
Read More... Posted Today in Clinical Trials.
-- JX-594 Selectivity is Multi-Mechanistic, Driven by Genetic
Traits Common in Solid Tumors --
SAN FRANCISCO, Feb. 7, 2012 /PRNewswire/ -- Jennerex, Inc., a
private clinical-stage biotherapeutics company focused on the
development and commercialization of first-in-class targeted
oncolytic virus products for cancer, today announced the
publication in Molecular Therapy of data validating the...
Read More... Posted Today in Clinical Trials.
DENVER--(BUSINESS WIRE)--Feb 7, 2012 - Cannabis Science, Inc.
(OTCBB:CBIS) a pioneering U.S. biotech company developing
pharmaceutical cannabis (marijuana) products, is pleased to present
the newest set of photographs showing evidence that the cancer
cells appear to have been killed over the course of treatment from
the 2nd self-administering cancer patient suffering from squamous
cell carcinoma...
Read More... Posted Today in Clinical Trials.
PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - Anacor
Pharmaceuticals (NASDAQ:ANAC) announced today positive preliminary
results from two safety studies of AN2728 - a maximal use systemic
exposure (MUSE) study in psoriatic patients and a local
tolerability study. The results of these two studies demonstrate
that AN2728 Ointment, 2% appears to be safe and well-tolerated when
applied to very...
Read More... Posted Today in Clinical Trials.
Preclinical Research Validates Role of BMP Pathway in
Treating Progressive Kidney Disease and Potential for Thrasos'
Compounds to Selectively Target the Pathway
MONTREAL--(BUSINESS WIRE)--Feb 7, 2012 - Thrasos today announced
that the journal Nature Medicine has published the results
of a collaborative research program detailing the role of the bone
morphogenic protein (BMP) pathway in the...
Read More...
